Rhenman & Partners Asset Management Ab Seagen Inc. Transaction History

Rhenman & Partners Asset Management Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $569,216 - $757,902	-4,208 Reduced 9.31%	41,000 $5.21 Million
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $1.72 Million - $2.83 Million	-15,792 Reduced 25.89%	45,208 $8 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $7.89 Million - $10.4 Million	-66,000 Reduced 51.97%	61,000 $8.79 Million
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $1.14 Million - $1.53 Million	-8,000 Reduced 5.93%	127,000 $20 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $3.27 Million - $3.89 Million	-22,925 Reduced 14.52%	135,000 $22.9 Million

Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $10.5 Million - $12.6 Million	77,925 Added 97.41%	157,925 $24.9 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $2.06 Million - $2.86 Million	15,000 Added 23.08%	80,000 $11.1 Million
Q4 2020 Jan 19, 2021	BUY	$164.63 - $211.93 $10.7 Million - $13.8 Million	65,000 New	65,000 $11.4 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.